Moderna
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta
Zacks.com highlights biotech stocks, focusing on Q4 earnings and regulatory updates. Moderna beat earnings estimates, reaffirmed 2024 sales guidance, and expects RSV vaccine approval. RAPT Therapeutics faced a clinical hold due to a liver failure case. Iovance surged after FDA approval for melanoma treatment. Sarepta seeks label expansion for DMD drug. Regeneron's myeloma drug gets Priority Review.
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates
Amylyx Pharmaceuticals' shares fell after its ALS treatment failed in a phase III study. Acadia Pharmaceuticals also saw a decline due to a failed schizophrenia treatment study. Regulus Therapeutics reported positive results for a kidney disease treatment, boosting its shares. Moderna initiated a cancer therapy study, increasing its stock value. Regeneron received FDA approval to extend its cholesterol drug's label to pediatric patients.
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
The article highlights 12 undervalued biotech stocks favored by hedge funds, focusing on companies like MEI Pharma, Ocuphire Pharma, and Voyager Therapeutics. It discusses the biotech industry's growth, driven by innovation, M&A activity, and FDA approvals, with a positive outlook for 2024 despite challenges like drug pricing and regulatory scrutiny.
On 4-year anniversary of the WHO declaring COVID a pandemic, a look at the virus by the numbers
Over 1.18 million Americans have died from COVID-19 since the pandemic began, with hospitalizations and deaths significantly lower than peaks. Vaccinations and treatments have reduced severity, but uptake is low. Long COVID affects millions, and 9,655 children have developed MIS-C, with 79 deaths.
Moderna pitches RSV shot, new vaccines after 'difficult year of challenges'
Moderna's shares surged 10% after reporting a Q4 profit surpassing expectations, despite a 2/3 sales drop to $6.7B in 2023 due to lower COVID vaccination rates. The company forecasts $4B in 2024 sales, partly from an RSV vaccine under review, and is developing a flu-COVID combo shot for future growth.
Two very rare Covid vaccine side-effects detected in global study of 99 million
A study of over 99 million people identified two new rare Covid-19 vaccine side effects: acute disseminated encephalomyelitis and transverse myelitis, linked to the AstraZeneca vaccine. The research confirmed known rare side effects of vaccines, emphasizing the benefits vastly outweigh the risks. Findings were published in the journal Vaccine.
Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates
Moderna reported Q4 2023 earnings of 55 cents per share, surpassing expectations, with $2.8 billion in revenue, mainly from COVID-19 Vaccine Spikevax sales. It expects RSV vaccine approvals in 2024. RAPT Therapeutics faced a clinical hold on zelnecirnon trials due to a liver failure case, halting dosing and new enrollments. Iovance Biotherapeutics' stock surged after FDA accelerated approval of Amtagvi for melanoma treatment, based on phase II study results showing effective responses.
Top 10 Most Anticipated Drug Launches Of 2024
In 2023, FDA's CDER approved 55 new drugs, a five-year high. Key 2024 drug launches include KarXT for schizophrenia, Donanemab for Alzheimer's, Resmetirom for NASH, Sotatercept for PAH, Datopotamab deruxtecan for lung & breast cancer, Acoramidis for ATTR-CM, mRNA-1345 for RSV, Anktiva for NMIBC, Ensifentrine for COPD, and Imetelstat for MDS.
New COVID vaccines OK'd by FDA, escaped convict search: 5 Things podcast
FDA approved updated COVID-19 vaccines targeting a new variant, with guidance for immunocompromised and older adults to get vaccinated. Over 2,800 died in Morocco's earthquake; international aid is coordinated. An escaped convict in Pennsylvania remains at large. Military efforts in Alaska recover remains from a 1952 plane crash. The U.S. set a record for natural disasters in 2023.
© Copyright 2025. All Rights Reserved by MedPath